On June 16, 2021, Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, announced that it has raised $66 million in an oversubscribed Series C financing. The financing was co-led by The Column Group and Nextech Invest. All investors from the prior round participated in the Series C, including Pandect Bioventures, together with new investors including Euclidean Capital, Pavillion Capital, Hartford HealthCare Endowment, and Eli Lilly and Company. Wilson Sonsini Goodrich & Rosati represented Circle Pharma in the transaction.

Proceeds from the financing will be used to advance the Circle Pharma's wholly owned cyclin-targeted programs towards the clinic, with potential applications in Rb-dysregulated cancers such as small cell lung cancer and cyclin E dependent malignancies, including ovarian cancer. In addition, the company will apply its macrocycle platform to other precision oncology targets that have a clear therapeutic rationale but are considered undruggable with small molecules.

The Wilson Sonsini team that advised Circle Pharma on the transaction includes Elton Satusky, Jesse Schumaker, and Kathy Jordan.

For more information, please see Circle Pharma's press release.